Johnson & Johnson (NYSE:JNJ) is yet again making headlines after the pharmaceutical company was granted FDA approval for their new booster shot.
Q3 2021 hedge fund letters, conferences and more
Disclaimer: This is a satirical article.
Johnson & Johnson boasted about its lack of safety, citing “We out did ourselves with this one. Our new booster shot is now 79% more likely to cause blood clots, as to our previous jab which only had a roughly 32.5% chance at giving one a blood clot.”
Johnson & Johnson shares soared on the good news.
This post first appeared on The Stonk Market
Disclaimer: This is a satirical article.
